Achaogen (AKAO) announced that it has completed enrollment of 609 subjects in its Phase 3 clinical trial evaluating plazomicin for the treatment of patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP) (kidney infection). The primary objective is to demonstrate non-inferiority to meropenem (within a 15% margin) as determined by the difference in composite microbiological eradication and clinical cure rate in the intent-to-treat population at both Day 5 and test-of-cure visits. Separately, enrollment has been closed in the Phase 3 CARE study assessing plazomicin with the antibiotic colistin, in combination with a second antibiotic (meropenem or tigecycline), for the treatment of blood stream infections, hospital-acquired pneumonia or ventilator-associated bacterial pneumonia due to carbapenem-resistant enterobacteriaceae (CRE). The primary endpoint is all-cause mortality at Day 28 or significant disease-related complications in Cohort 1 (n=39) at Day 28.